Goldfarb Branham Law Firm LLP Investigates Allos Therapeutics Inc Company

Goldfarb Branham LLP is investigating whether the board of Allos Therapeutics (NASDAQ: ALTH) violated shareholder protection laws in connection with approving the buyout with AMAG Pharmaceuticals for $2.44 per share in AMAG stock. Concerned Allos Therapeutics stockholders are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com to discuss their rights and remedies.

“Analysts have set target prices far in excess of the current offer— between $3.00 and $8.00 per share,” said Hamilton Lindley, a securities lawyer with Goldfarb Branham. “Additionally, the company’s future looks bright because it reported surging sales of 47% for one of the company’s signature products. Our proposed shareholder lawsuit seeks to ensure that the Allos Therapeutics stockholders get the highest price reasonably available and disclosure of all important information about the buyout.”

Goldfarb Branham LLP represents individual and institutional shareholders in securities litigation nationwide. The firm has been selected as lead counsel on high profile shareholder lawsuits. Current Allos Therapeutics shareholders with questions or concerns, or individuals with knowledge about the allegations in the complaints, should contact securities lawyer Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com.

Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024